A PHASE 1B DOUBLE-BLINDED PLACEBO-CONTROLLED RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ASCENDING DOSES OF PF-06342674 (RN168) IN SUBJECTS WITH MULTIPLE SCLEROSIS (MS)
D
David Mattson, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
100 years or below
All
Phase
N/A
1 Location
Brief description of study
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of subcutaneous infections of PF-06342674 in subjects with multiple sclerosis.
Detailed description of study
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of subcutaneous infections of PF-06342674 in subjects with multiple sclerosis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: multiple sclerosis
-
Age: 100 years or below
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 1408766148
